



(12) Translation of
European patent specification

(11) NO/EP 3250208 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/519 (2006.01)
C07D 471/12 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2021.03.01

(80) Date of The European Patent Office Publication of the Granted Patent 2020.09.30

(86) European Application Nr. 16744237.5

(86) European Filing Date 2016.01.29

(87) The European Application's Publication Date 2017.12.06

(30) Priority 2015.01.30, US, 201562109737 P
2015.04.17, US, 201562148844 P
2015.09.28, US, 201562233757 P

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

Designated Extension States: BA ; ME

(73) Proprietor Oncoceutics, Inc., 3675 Market Street Suite 200, Philadelphia, PA 19104, USA

(72) Inventor STOGNIEW, Martin, 7811 Mathern Ct.Lakewood Ranch,, Florida 34202, USA
ALLEN, Joshua E., 43 Chestnut St., Unit 311, New Haven, Connecticut 06511, USA
POTTORF, Richard S., 7550 Prairie View Dr., Indianapolis, Indiana 46526, USA
NALLAGANCHU, Bhaskara Rao, 99 Nostrand Road, Hillsborough, New Jersey 08852, USA
OLSON, Gary L., 1505 Coles Avenue, Mountainside, New Jersey 07092, USA
SUN, Yanjun, 14 Greyhound Court, Kendall Park, New Jersey 08824, USA

(74) Agent or Attorney Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, 92665 ASNIÈRES-SUR-SEINE CEDEX, Frankrike

(54) Title **7-BENZYL-4-(4-(TRIFLUOROMETHYL)BENZYL)-1,2,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(4H)-ONE AND SALTS THEREOF AND THEIR USE IN THERAPY**

(56) References Cited: WO-A1-2015/153468
WO-A2-2012/149546
DE-A1- 2 150 062
US-A1- 2014 271 540
US-A1- 2014 335 048
US-B2- 6 869 958

DATABASE PUBCHEM [Online] 07 February 2014 XP055468537 Retrieved from NCBI
Database accession no. CID 72716768

JACOB ET AL.: 'Pharmacophore Reassignment for Induction of the Immunosurveillance
Cytokine TRAIL' ANGEW.CHEM. INT. ED. vol. 53, no. 26, 18 May 2014, pages 6628 - 6631,
XP055259380


JACOB ET AL.: 'Pharmacophore Reassignment for Induction of the Immunosurveillance
Cytokine TRAIL' ANGEW.CHEM. INT. ED. vol. 53, no. 26, 16 May 2014, pages 6628 - 6631,
XP055259380

MOSS G P ET AL: "Glossary of class names of organic compounds and reactivity intermediates
based on structure (IUPAC Recommendations 1995)", PURE & APPLIED CHEM, PERGAMON
PRESS, OXFORD, GB, vol. 67, no. 8/9, 1 January 1995 (1995-01-01), pages 1307-1375,
XP007914773, ISSN: 0033-4545, DOI: 10.1351/PAC199567081307

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse som oppviser den følgende strukturen:



eller et farmasøytisk akseptabelt salt av samme.

- 5 2. Blanding som omfatter et salt av forbindelsen ifølge krav 1.
3. Blanding ifølge krav 2, hvori saltet er et di-salt.
4. Blanding ifølge krav 3, hvori di-saltet er et hydroklorid-di-salt.
5. Farmasøytisk blanding som omfatter en forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt av samme og en farmasøytisk akseptabel bærer.
- 10 6. Forbindelse ifølge krav 1, eller en blanding ifølge ett av kravene 2-4, eller en farmasøytisk blanding ifølge krav 5, for anvendelse som et medikament.
7. Forbindelse ifølge krav 1, eller en blanding ifølge ett av kravene 2-4, eller en farmasøytisk blanding ifølge krav 5, for anvendelse i behandling av kreft.